Zanidatamab 联合化疗加或减 Tislelizumab 治疗 HER2 阳性晚期或转移性胃癌和食管癌患者的研究 (HERIZON-GEA-01)
Zanidatamab 联合化疗联合或不联合 Tislelizumab 治疗 HER2 阳性不可切除局部晚期或转移性胃食管腺癌 (GEA) 患者的随机、多中心、3 期研究
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
研究概览
地位
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Beijing、中国、101199
- Beijing Luhe Hospital, Capital Medical University
-
Beijing、中国、100020
- Beijing Chao-Yang Hospital, Capital Medical University
-
Bengbu、中国、233004
- The First Affiliated Hospital of Bengbu Medical College
-
Changsha、中国、410031
- Hunan Cancer Hospital
-
Changzhi、中国、046099
- Changzhi People's Hospital
-
Changzhou、中国、213004
- Changzhou First People's Hospital
-
Chengdu、中国、610042
- Sichuan Cancer Hospital & Institute
-
Fuzhou、中国、350014
- Fujian Cancer Hospital
-
Fuzhou、中国、350005
- The First Affiliated Hospital of Fujian Medical University
-
Guangzhou、中国、510655
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
Guangzhou、中国、510055
- Guangdong Provincial People's Hospital
-
Haikou、中国、570311
- Hainan General Hospital
-
Hangzhou、中国、310016
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
-
Hangzhou、中国、310022
- Zhejiang Cancer Hospital
-
Hangzhou、中国、310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
Hangzhou、中国、310017
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Harbin、中国、150081
- Harbin Medical University Cancer Hospital
-
Hefei、中国、230601
- The Second Affiliated Hospital of Anhui Medical University
-
Hefei、中国、230031
- Anhui Provincial Cancer Hospital
-
Hohhot、中国、01000
- Affiliated Hospital of Inner Mongolia Medical University
-
Jinan、中国、250013
- Jinan Central Hospital
-
Jinan、中国、250000
- Shandong Cancer Hospital
-
Kunming、中国、650118
- Yunnan Cancer Hospital
-
Lanzhou、中国、730050
- Gansu Cancer Hospital
-
Lanzhou、中国、730013
- The First Hospital of Lanzhou University
-
Nanchang、中国、330052
- The First Affiliated Hospital of Nanchang University
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
-
Qingdao、中国、266003
- The Affiliated Hospital of Qingdao University
-
Shanghai、中国、200032
- Fudan University Shanghai Cancer Center
-
Shanghai、中国、200080
- Shanghai General Hospital
-
Shanghai、中国、200032
- Fudan University Affiliated Zhongshan Hospital
-
Shanghai、中国、200025
- Ruijin hospital Shanghai Jiao Tong University School of Medicine
-
Shenyang、中国、110801
- Liaoning Cancer Hospital & Institute
-
Shijiazhuang、中国、50011
- The Fourth Hospital of Hebei Medical University
-
Tianjin、中国、300060
- Tianjin Medical University Cancer Institute & Hospital
-
Tianjin、中国、300041
- Tianjin Medical University General Hospital
-
Tonghua、中国、143099
- The Tonghua Central Hospital
-
Weihai、中国、264200
- Weihai Municipal Hospital
-
Wenzhou、中国、325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan、中国、430079
- Hubei Cancer Hospital
-
Wuhan、中国、430023
- Union Hospital Tongji Medical College HuaZhong University of Science and Technology
-
Wuxi、中国、214062
- Affiliated Hospital of Jiangnan University
-
Xi'an、中国、710061
- First Affiliated Hospital of Xi 'an Jiaotong University
-
Xiamen、中国、361003
- The First Affiliated Hospital of Xiamen University
-
Yangzhou、中国、225001
- Northern Jiangsu People's Hospital
-
Zhengzhou、中国、450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou、中国、450003
- Henan Cancer Hospital
-
Ürümqi、中国、830026
- Cancer Hospital affiliated to Xinjiang Medical University
-
-
-
-
-
Dnipropetrovsk、乌克兰、49102
- Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
-
-
-
-
-
Tbilisi、乔治亚州、0112
- Research Institute of Clinical Medicine
-
Tbilisi、乔治亚州、6000
- High Technology Hospital MedCenter Ltd
-
-
-
-
-
Toronto、加拿大、M5G 2C1
- Princess Margaret Cancer Centre
-
-
-
-
-
Pretoria、南非、0184
- Wilgers Oncology Centre
-
-
-
-
-
Bhubaneswar、印度、751019
- All India Institute of Medical Sciences, Bhubaneswar
-
Gūrgaon、印度、122003
- Artemis Hospital
-
Hyderabad、印度、500004
- MNJ Institute of Oncology and Regional Cancer Centre
-
New Delhi、印度、110076
- Indraprastha Apollo Hospitals
-
Patna、印度、800014
- Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
-
Vijayawada、印度、520002
- HCG City Cancer Center
-
-
-
-
-
Guatemala City、危地马拉、01010
- Clinica Medica Especializada CELAN
-
Guatemala City、危地马拉、01015
- Grupo Medico Angeles
-
Salcajá、危地马拉、09002
- Centro Medico Integral de Cancerologia CEMIC
-
-
-
-
-
Taichung、台湾、404472
- China Medical University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
-
-
-
Ankara、土耳其(türkiye)、06230
- Hacettepe Universitesi Kanser Enstitusu
-
Edirne、土耳其(türkiye)、22030
- Trakya University Medical Faculty
-
Izmir、土耳其(türkiye)、35220
- Dokuz Eylul Universitesi
-
Seyhan、土耳其(türkiye)、01130
- Acibadem Adana Hospital
-
Trabzon、土耳其(türkiye)、61310
- Medical Park Trabzon Yildizli
-
Yenimahalle、土耳其(türkiye)、06200
- Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
-
-
-
-
-
Belgrade、塞尔维亚、11070
- Clinical Hospital Center Bezanijska Kosa
-
Belgrade、塞尔维亚、11000
- University Clinical Center of Serbia - PPDS
-
Kamenitz、塞尔维亚、21204
- Oncology Institute of Vojvodina
-
Niš、塞尔维亚、18000
- University Clinical Center Nis
-
-
-
-
-
Mexico City、墨西哥、03100
- Health Pharma Professional Research S.A de C.V.
-
Monterrey、墨西哥、64460
- Hospital Universitario Dr. Jose Eleuterio González
-
Oaxaca City、墨西哥、68020
- Centro de Investigacion Clinica de Oaxaca
-
-
-
-
-
Barretos、巴西、14784-400
- Centro Integrado de Pesquisa - CIP
-
Barretos、巴西、14784-400
- Fundação Pio XII Hospital de Câncer de Barretos
-
Belo Horizonte、巴西、30130-090
- Cenantron - Centro Avancado de Tratamento Oncologico Ltda
-
Brasília、巴西、70840-901
- Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
-
Fortaleza、巴西、60430-230
- Instituto Do Câncer Do Ceará ICC
-
Porto Alegre、巴西、90050-170
- Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
-
Porto Alegre、巴西、90050-170
- Irmandade Da Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre、巴西、91350-200
- Hospital Nossa Senhora Da Conceição
-
Santo André、巴西、09060-650
- Núcleo de Pesquisa Clínica da Rede São Camilo
-
Sorocaba、巴西、18030-075
- Instituto de Oncologia de Sorocaba
-
São Paulo、巴西、01246-000
- Instituto do Cancer do Estado de São Paulo ICESP
-
-
-
-
-
Athens、希腊、124 64
- Attikon University General Hospital
-
Thessaloniki、希腊、552 36
- Agios Loucas Clinic SA
-
Thessaloniki、希腊、54622
- Bioclinic Thessaloniki Oncology Department
-
Thessaloniki、希腊、57001
- Interbalkan Medical Center of Thessaloniki Oncology Department
-
-
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60488
- Institut für Klinisch-Onkologische Forschung
-
-
-
-
-
Bologna、意大利、40138
- Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
-
Candiolo、意大利、10060
- Fondazione del Piemonte per l'Oncologia (IRCCS)
-
Genova、意大利、16132
- Ospedale Policlinico San Martino
-
Meldola、意大利、47014
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
-
Milan、意大利、20132
- Ospedale San Raffaele S.r.l. - PPDS
-
Milan、意大利、20162
- ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
-
Milan、意大利、20133
- Istituto Nazionale Dei Tumori
-
Modena、意大利、41124
- Azienda Ospedaliero Universitaria Di Modena Policlinico
-
Reggio Emilia、意大利、43100
- Arcispedale Santa Maria Nuova
-
Rome、意大利、00168
- Fondazione Policlinico Universitario A Gemelli
-
Verona、意大利、37134
- Centro Ricerche Cliniche Di Verona
-
Vicenza、意大利、36100
- Azienda ULSS 8 "Berica" - Ospedale San Bortolo
-
-
-
-
-
Singapore、新加坡、258500
- National Cancer Center Singapore
-
-
-
-
-
Chūōku、日本、104-0045
- National Cancer Center Hospital
-
Fukuoka、日本、811-1395
- National Hospital Organization Kyushu Cancer Center
-
Ina、日本、362-0806
- Saitama Cancer Center
-
Matsuyama、日本、791-0245
- Shikoku Cancer Center
-
Osaka、日本、540-0008
- Osaka International Cancer Institute
-
Tokyo、日本、135-8550
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research
-
Ōsaka-sayama、日本、589-0014
- Kindai University Hospital
-
-
Chiba
-
Chiba、Chiba、日本、260-0801
- Chiba Cancer Center
-
Kashiwa-shi、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Gihu
-
Gifu、Gihu、日本、501-1112
- Gifu University Hospital
-
-
Gunma
-
Ota-shi、Gunma、日本、373-8550
- Gunma Prefectural Cancer Center
-
-
Hyôgo
-
Akashi-shi、Hyôgo、日本、673-8558
- Hyogo Cancer Center
-
-
Ibaraki
-
Kasama-Shi、Ibaraki、日本、309-1793
- Ibaraki Prefectural Central Hospital
-
-
Kagawa-ken
-
Kita-Gun Miki-Cho、Kagawa-ken、日本、761-0701
- Kagawa University Hospital
-
-
Kanagawa
-
Yokohama-Shi Asahi-Ku、Kanagawa、日本、241-0815
- Kanagawa Cancer Center
-
-
Kumamoto
-
Chuo-Ku、Kumamoto、日本、860-8556
- Kumamoto University Hospital - Honjo-Kuhonji Campus A
-
-
Kyoto-shi
-
Sakyo-ku、Kyoto-shi、日本、606-8507
- Kyoto University Hospital
-
-
Miyagi
-
Osaki-Shi、Miyagi、日本、989-6136
- Osaki Citizen Hospital
-
-
Okayama-ken
-
Kurashiki-Shi、Okayama-ken、日本、710-0052
- Kurashiki Central Hospital
-
-
Osaka
-
Suita-Shi、Osaka、日本、565-0871
- Osaka University Hospital
-
Takatsuki-Shi、Osaka、日本、569-8686
- Osaka Medical and Pharmaceutical University Hospital
-
-
Tokyo
-
Shinjuku-Ku、Tokyo、日本、160-8582
- Keio University Hospital
-
-
-
-
-
Providencia、智利、7500000
- Centro de Estudios Clínicos SAGA SpA
-
Santiago、智利、7500000
- Sociedad Oncovida S.A
-
Santiago、智利、8150513
- Icegclinic
-
Santiago、智利、8330336
- BIOCINETIC SpA
-
Temuco、智利、4810469
- Sociedad de Investigaciones Medicas Limitada
-
-
Region Metropolitan
-
Santiago、Region Metropolitan、智利、8420383
- Centro Internacional de Estudios Clinicos CIEC
-
-
Santiago Metropolitan
-
Providencia、Santiago Metropolitan、智利、7500000
- Fundación Arturo López Pérez (FALP) - PPDS
-
-
-
-
-
Bonheiden、比利时、2820
- Imelda VZW
-
Brussels、比利时、1200
- Cliniques Universitaires Saint-Luc
-
Ghent、比利时、9000
- UZ Gent
-
Leuven、比利时、3000
- UZ Leuven
-
Liège、比利时、4000
- CHU de Liège
-
-
-
-
-
Avignon、法国、84000
- Sainte-Catherine, Institut du Cancer Avignon Provence
-
Bordeaux、法国、33000
- EDOG - Institut Bergonie - PPDS
-
Dijon、法国、21079
- Universite de Bourgogne - Faculte de Medecine - IN
-
Grenoble、法国、38043
- Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
-
Lyon、法国、69008
- Centre Léon Berard
-
Nantes、法国、44805
- EDOG Institut de Cancerologie de l'Ouest - PPDS
-
Poitiers、法国、86021
- CHRU de Poitiers La Miletrie
-
Rennes、法国、35000
- EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
-
Saint-Priest-en-Jarez、法国、42270
- CHRU de Brest - Hopital Morvan
-
Toulouse、法国、69437
- Hôpital de Rangueil
-
Villejuif、法国、94800
- Hôpital Saint Antoine
-
-
Gironde
-
Pessac、Gironde、法国、33600
- CHU de Bordeaux - Hopital Haut Leveque
-
-
-
-
-
Lodz、波兰、93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
-
Warsaw、波兰、02-034
- Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
-
-
-
-
-
Hat Yai、泰国、90110
- Songklanagarind Hospital
-
Khon Kaen、泰国、40000
- Srinagarind Hospital, Khon Kaen University
-
Lak Si、泰国、10210
- Chulaborn Hospital
-
-
-
-
-
Bedford Park、澳大利亚、5042
- Flinders Medical Centre
-
Heidelberg、澳大利亚、3084
- Austin Health
-
Liverpool、澳大利亚、2170
- Liverpool Hospital
-
Murdoch、澳大利亚、6150
- Fiona Stanley Hospital
-
-
-
-
-
Dublin、爱尔兰、8
- St James's Hospital
-
-
-
-
-
Tallinn、爱沙尼亚、13419
- North Estonia Medical Centre Foundation
-
-
-
-
-
Bucharest、罗马尼亚、022328
- Fundeni Clinical Institute
-
Cluj-Napoca、罗马尼亚、400015
- Prof Dr I Chiricuta Institute of Oncology - PPDS
-
Cluj-Napoca、罗马尼亚、400641
- Medisprof SRL
-
Craiova、罗马尼亚、200347
- Oncology Center Sfantul Nectarie
-
-
-
-
-
Bristol、英国、BS2 8ED
- Bristol Haematology and Oncology Centre
-
Edinburgh、英国、EH4 2XU
- Western General Hospital Edinburgh - PPDS
-
Leeds、英国、LS9 7TF
- St James University Hospital
-
London、英国、SE1 9RT
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
London、英国、SW7 3RP
- Royal Marsden Hospital - London
-
London、英国、SW7 3RP
- Royal Marsden Hospital - Surrey
-
Peterborough、英国、PE3 9GZ
- Edith Cavell Hospital
-
Sheffield、英国、S10 2SJ
- Weston Park Cancer Centre
-
-
-
-
-
Eindhoven、荷兰、5623 EJ
- Catharina Hospital
-
Leiden、荷兰、2333 ZA
- Leids Universitair Medisch Centrum
-
Tilburg、荷兰、5042 AD
- ETZ-Elisabeth
-
-
-
-
-
Almada、葡萄牙、2801-951
- Hospital Garcia de Orta
-
Coimbra、葡萄牙、3000-459
- Centro Hospitalar E Universitário de Coimbra EPE
-
Guimarães、葡萄牙、4830-044
- Hospital Senhora da Oliveira - Guimaraes, E.P.E
-
Lisbon、葡萄牙、1649-035
- Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Matosinhos Municipality、葡萄牙、4454-509
- Unidade Local de Saúde de Matosinhos SA
-
Porto、葡萄牙、4200-072
- Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
-
Porto、葡萄牙、4099-001
- Centro Hospitalar do Porto EPE
-
-
-
-
-
Badalona、西班牙、8915
- Hospital Universitario Germans Trias i Pujol
-
Barcelona、西班牙、08035
- Hospital Universitario Vall d'Hebron - PPDS
-
Girona、西班牙、17007
- Hospital Universitari de Girona Dr Josep Trueta
-
L'Hospitalet de Llobregat、西班牙、08908
- Institut Català d'Oncologia (Hospital Duran y Reynals)
-
Madrid、西班牙、28034
- Hospital Universitario Ramon y Cajal
-
Madrid、西班牙、28046
- Hospital Universitario La Paz - PPDS
-
Málaga、西班牙、29010
- Hospital Regional Universitario de Malaga - Hospital General
-
Salamanca、西班牙、32911
- Complejo Asistencial Universitario de Salamanca - H. Clinico
-
Santander、西班牙、39008
- Hospital Universitario Marques de Valdecilla
-
Seville、西班牙、41009
- Hospital Universitario Virgen Macarena
-
Zaragoza、西班牙、50009
- Hospital Universitario Miguel Servet
-
-
Barcelona
-
Sabadell、Barcelona、西班牙、08208
- Corporacio Sanitaria Parc Tauli
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- Complejo Hospitalario de Navarra
-
-
-
-
-
Buenos Aires、阿根廷、C1181ACH
- Hospital Italiano de Buenos Aires
-
Buenos Aires、阿根廷、1264
- Hospital de Gastroenterología Dr Bonorino Udaondo
-
Buenos Aires、阿根廷、C1012
- Instituto de Investigaciones Metabólicas - IDIM
-
Córdoba、阿根廷、X5000HXL
- Fundación Centro de Medicina Nuclear y Molecular ER
-
Córdoba、阿根廷、X5008HHW
- Centro Médico Privado CEMAIC
-
Pergamino、阿根廷、2700
- Centro de Investigación Pergamino S.A.
-
Viedma、阿根廷、R8500ACE
- Centro de Investigación Clínica - Clínica Viedma
-
-
-
-
-
Anyang-si、韩国、14068
- Hallym University Sacred Heart Hospital
-
Busan、韩国、49201
- Dong-A University Hospital
-
Daegu、韩国、41404
- Kyungpook National University Chilgok Hospital
-
Goyang-si、韩国、10408
- National Cancer Center
-
Incheon、韩国、21565
- Gachon University Gil Medical Center
-
Seongnam-si、韩国、13620
- Seoul National University Bundang Hospital
-
Seongnam-si、韩国、13496
- CHA Bundang Medical Center, CHA University
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、06351
- Samsung Medical Center
-
Seoul、韩国、03181
- Kangbuk Samsung Hospital
-
Seoul、韩国、02841
- Korea University Anam Hospital
-
Seoul、韩国、08308
- Korea University Guro Hospital
-
Seoul、韩国、03080
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul、韩国、03686
- Severance Hospital Yonsei University Health System - PPDS
-
Seoul、韩国、06229
- Gangnam Severance Hospital, Yonsei University Health System
-
-
-
-
-
George Town、马来西亚、10990
- Hospital Pulau Pinang
-
Kuching、马来西亚、93586
- Sarawak General Hospital
-
Putrajaya、马来西亚、62675
- National Cancer Institute ( Institut Kanser Negara)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
- Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
- Adequate organ function
- Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)
Exclusion Criteria:
- Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
- Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
- Known history of or ongoing leptomeningeal disease (LMD)
- Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
- Known active hepatitis
- Any history of human immunodeficiency virus (HIV) infection
- Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
- QTc Fridericia (QTcF) > 470 ms
- Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm A
Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP) |
Administered intravenously (IV)
其他名称:
Administered orally (PO bid) Administered IV Administered IV Administered IV |
|
实验性的:Arm B
Zanidatamab plus physician's choice of CAPOX or FP |
Administered orally (PO bid) Administered IV Administered IV Administered IV Administered IV
其他名称:
|
|
实验性的:Arm C
Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP |
Administered orally (PO bid) Administered IV Administered IV Administered IV Administered IV
其他名称:
Administered IV |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free survival (PFS) by BICR
大体时间:Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause |
Up to 2.5 years
|
|
Overall survival
大体时间:Up to 3.5 years
|
The time from randomization to death due to any cause |
Up to 3.5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
扎尼达单抗和替雷利珠单抗的血清浓度
大体时间:最长 2 年
|
最长 2 年
|
|
|
Confirmed objective response rate (ORR) by BICR
大体时间:Up to 2.5 years
|
Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR |
Up to 2.5 years
|
|
Duration of response (DOR) by BICR
大体时间:Up to 2.5 years
|
The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause |
Up to 2.5 years
|
|
PFS per Investigator assessment
大体时间:Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause |
Up to 2.5 years
|
|
Confirmed ORR per Investigator assessment
大体时间:Up to 2.5 years
|
Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator |
Up to 2.5 years
|
|
DOR per Investigator assessment
大体时间:Up to 2.5 years
|
The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause |
Up to 2.5 years
|
|
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
大体时间:Up to 2.5 years
|
The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause |
Up to 2.5 years
|
|
Assessment of Contribution of Components based on Overall Survival
大体时间:Up to 3.5 years
|
The time from randomization to death due to any cause |
Up to 3.5 years
|
|
Incidence of adverse events
大体时间:Up to 2 years
|
Number of subjects who experienced adverse events or serious adverse events |
Up to 2 years
|
|
Incidence of clinical laboratory abnormalities
大体时间:Up to 2 years
|
Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 |
Up to 2 years
|
|
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
大体时间:Up to 2.5 years
|
Changes from baseline in the EORTC QLQ-C30 scores |
Up to 2.5 years
|
|
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
大体时间:Up to 2.5 years
|
Changes from baseline in the EORTC QLQ-OG25 scores |
Up to 2.5 years
|
|
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
大体时间:Up to 2.5 years
|
Changes from baseline in the EORTC EQ-5D-5L questionnaire scores |
Up to 2.5 years
|
|
Incidence of anti-drug antibodies (ADAs)
大体时间:Up to 2 years
|
Number of patients who develop ADAs |
Up to 2 years
|
合作者和调查者
出版物和有用的链接
一般刊物
- Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24.
- Lee KW, Bai LY, Jung M, Ying J, Im YH, Oh DY, Cho JY, Oh SC, Chao Y, Kim JW, Chen Y, Li V, Chen S, Kang YK. Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2026 Jan 16;32(2):312-323. doi: 10.1158/1078-0432.CCR-24-4295.
- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.
- Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L; HERIZON-GEA-01 Investigators. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28;394(20):2002-2014. doi: 10.1056/NEJMoa2517729.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- ZWI-ZW25-301
- 2021-000296-36 (EudraCT编号)
- jRCT2061230026 (注册表标识符:Japan Registry for Clinical Trials (jRCT))
- 2023-510319-20-00 (克蒂斯)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.